Key Points from the Annual Report

• Company Structure: ProKidney transitioned from ProKidney Cayman to ProKidney Delaware. References to “we”, “us”, “our”, and “the Company” apply to both entities depending on the period. Shareholders should note that “common stock” refers to “ordinary shares” before the domestication and “common stock” after. This affects voting and governance rights.
• Securities Registration: Class A common stock (\$0.0001 par value per share) is registered and listed on the Nasdaq Stock Market. No securities are registered pursuant to Section 12(g) of the Act. Shares outstanding as of March 17, 2026: 141,942,905 Class A and 159,973,180 Class B. These figures are crucial for evaluating dilution and market capitalization.
• Reporting Status and Compliance:
  • ProKidney is a well-known seasoned issuer and a smaller reporting company.
  • The company is NOT an emerging growth company.
  • All required SEC reports and interactive data files have been filed timely.
  • There has been no correction of errors or restatements in financial statements.
  • ProKidney is not a shell company.
• Principal Risk Factors:
  • ProKidney does not have any products approved for sale and thus generates no revenue from product sales.
  • The company’s ability to achieve profitability is uncertain and depends on successful drug development and commercialization.
  • There is an ongoing need for additional capital to fund drug development and commercialization efforts. Capital raises may dilute existing shareholders and affect rights related to drug candidates.
  • Failure in clinical trials or prioritizing the wrong research programs could result in significant financial and opportunity losses.
  • Manufacturing and commercialization risks include potential market acceptance, ability to establish sales and marketing capabilities, and regulatory approval across jurisdictions.
  • Legal and regulatory risks include ongoing compliance with healthcare laws, data privacy regulations, and global cost containment initiatives.
  • Intellectual property risks involve the possibility of unauthorized disclosure of trade secrets, litigation over IP, and challenges in obtaining patent term extensions for product candidates.
  • Operational risks include challenges in expanding and managing growth, influence of major investors, and provisions in governing documents or Delaware law that may delay or prevent acquisition.
  • Macroeconomic risks such as geopolitical uncertainty, stock market fluctuations, and possible changes to investor rights as a Delaware corporation.
• Potential Price-Sensitive Information:
  • Need for Additional Capital: The company has highlighted a need for further capital to continue operations and drug development. Any future capital raising (through equity, debt, or other instruments) could dilute current shareholders and impact share price.
  • Product Pipeline Risk: The lack of approved products and dependence on clinical trial outcomes creates significant uncertainty. Negative trial results or regulatory setbacks could materially impact share value.
  • Intellectual Property Vulnerabilities: Risks concerning trade secrets, patent protection, and possible litigation could affect the company’s competitive position and valuation.
  • Regulatory and Legal Uncertainty: Ongoing regulatory reviews and compliance requirements, especially as the company plans international operations, may lead to unforeseen costs or delays.
  • Major Shareholder Influence: Substantial influence of certain investors could affect strategic decisions, including mergers or acquisitions.
  • Market Risks: The company’s reliance on the status of a “well-known seasoned issuer” and “smaller reporting company” could affect regulatory requirements and investor perception.

Shareholder Considerations

• Capital Raising: Shareholders should monitor announcements regarding new capital raising as these could be dilutive and materially impact share price.
• Drug Development Milestones: Progress (or setbacks) in clinical trials or regulatory approvals are likely to be highly price-sensitive.
• Legal and Intellectual Property Events: Litigation, patent disputes, or major IP developments could significantly affect the company’s valuation and competitive position.
• Market Listing and Structure: Changes in share structure, governance, or major investor influence may impact voting power and potential for takeover or merger activity.

Forward-Looking Statements and Risks

The annual report contains numerous forward-looking statements reflecting the management’s plans, estimates, and assumptions as of the report date. These include business strategies, drug development, financing plans, and market opportunities. Actual results may differ materially due to the risks described above.

Investors should not place undue reliance on these forward-looking statements. The company is not obligated to update these statements even if new information becomes available.

Summary Table of Principal Risks

Conclusion

ProKidney’s Annual Report outlines a company at a critical juncture, with significant risks and capital needs, but also potential for transformative developments pending successful clinical trials and commercialization. Investors should closely monitor capital raising activities, clinical trial progress, and regulatory developments.